Can mild ALT elevation accompany metabolic fatty liver and hepatic insulin resistance?

Mild ALT elevation is compatible with metabolic dysfunction-associated steatotic liver disease (MASLD) and impaired hepatic insulin action, but is best treated as a signal for assessment—not a diagnosis.

Clinical and metabolic evidence

• Population MRI data link hepatic steatosis with higher ALT. In a 77-year-old man, an ALT above the approximate AASLD “true-normal” male range of 29–33 U/L may merit attention even if it falls within a laboratory’s broader reference interval.
• ALT can be normal in MASLD, including in steatohepatitis or advanced fibrosis; conversely, a mild elevation has many non-metabolic causes.
• Clamp/tracer studies associate higher ALT with reduced insulin-mediated suppression of endogenous glucose production and lower hepatic insulin sensitivity. Prospective evidence also links higher ALT with subsequent worsening of hepatic glucose production and incident type 2 diabetes, but this is predictive association rather than proof that ALT causes diabetes.

Mechanistic interpretation

• Liver fat is biologically closer to hepatic insulin resistance than ALT: intrahepatic triglyceride content independently predicts hepatic insulin action and is more strongly related to hepatic insulin sensitivity than ALT.
• ALT likely reflects, imperfectly, hepatocellular injury or metabolic liver stress. It does not directly measure liver fat, inflammation, fibrosis, or insulin signaling.

Practical diagnostic implications

• MASLD assessment requires evidence of steatosis (imaging, biomarker, or histology), cardiometabolic risk assessment, and consideration of alcohol exposure and other causes of liver disease. CAP or MRI-PDFF can assess liver fat; conventional ultrasound is less sensitive.
• A persistent mild ALT elevation should prompt repeat liver tests and review of alcohol, medications/supplements, viral hepatitis, autoimmune disease, iron overload, and other indicated etiologies. Fibrosis risk assessment should not rely on ALT alone.

Bottom line

• The claim is supported: mild ALT elevation can accompany both MASLD and hepatic insulin resistance, but ALT alone is neither sensitive nor specific enough to establish either condition in an individual.